Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis.

Castañeda X, García-de-la-Mària C, Gasch O, Pericas JM, Armero Y, Soy D, García-González J, Falces C, Ninot S, Almela M, Ambrosioni J, Quintana E, Vidal B, Fuster D, Llopis J, Soto S, Moreno A, Marco F, Miró JM; Hospital Clinic Endocarditis Study Group.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02486-16. doi: 10.1128/AAC.02486-16. Print 2017 Jun.

2.

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Garcia-de-la-Maria C, Xiong YQ, Pericas JM, Armero Y, Moreno A, Mishra NN, Rybak MJ, Tran TT, Arias CA, Sullam PM, Bayer AS, Miro JM.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02418-16. doi: 10.1128/AAC.02418-16. Print 2017 May.

3.

Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.

Pericàs JM, García-de-la-Mària C, Brunet M, Armero Y, García-González J, Casals G, Almela M, Quintana E, Falces C, Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Miró JM; Hospital Clinic Endocarditis Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1714-1722. doi: 10.1093/jac/dkx016.

PMID:
28204495
4.

Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

del Río A, García-de-la-Mària C, Entenza JM, Gasch O, Armero Y, Soy D, Mestres CA, Pericás JM, Falces C, Ninot S, Almela M, Cervera C, Gatell JM, Moreno A, Moreillon P, Marco F, Miró JM; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):478-86. doi: 10.1128/AAC.02139-15. Print 2016 Jan.

5.

Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.

García de la Mària C, Cervera C, Pericàs JM, Castañeda X, Armero Y, Soy D, Almela M, Ninot S, Falces C, Mestres CA, Gatell JM, Moreno A, Marco F, Miró JM; Hospital Clinic Endocarditis Study Group.

PLoS One. 2015 May 11;10(5):e0125818. doi: 10.1371/journal.pone.0125818. eCollection 2015.

6.

Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.

Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, Falces C, Ninot S, Castañeda X, Armero Y, Soy D, Gatell JM, Marco F, Mestres CA, Miro JM; Hospital Clinic Endocarditis Study Group.

Clin Microbiol Infect. 2014 Dec;20(12):O1075-83. doi: 10.1111/1469-0691.12756. Epub 2014 Aug 11.

7.

Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.

Cervera C, Castañeda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericas JM, Falces C, Armero Y, Almela M, Ninot S, Pare JC, Mestres CA, Gatell JM, Marco F, Miro JM; Hospital Clinic Endocarditis Study Group.

Clin Infect Dis. 2014 Jun;58(12):1668-75. doi: 10.1093/cid/ciu183. Epub 2014 Mar 18.

PMID:
24647021
8.

Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.

García-de-la-Mària C, Pericas JM, Del Río A, Castañeda X, Vila-Farrés X, Armero Y, Espinal PA, Cervera C, Soy D, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Vila J, Moreno A, Marco F, Miró JM; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2013 May;57(5):2319-25. doi: 10.1128/AAC.01921-12. Epub 2013 Mar 11.

9.

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Miró JM, Entenza JM, Del Río A, Velasco M, Castañeda X, Garcia de la Mària C, Giddey M, Armero Y, Pericàs JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. Epub 2012 May 29.

10.

Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.

García-de-la-Mària C, Marco F, Armero Y, Soy D, Moreno A, del Río A, Almela M, Cervera C, Ninot S, Falces C, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM; Hospital Clínic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2010 Jul;54(7):2781-6. doi: 10.1128/AAC.01011-09. Epub 2010 Apr 26.

11.

Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Miró JM, García-de-la-Mària C, Armero Y, Soy D, Moreno A, del Río A, Almela M, Sarasa M, Mestres CA, Gatell JM, Jiménez de Anta MT, Marco F; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2009 Oct;53(10):4172-7. doi: 10.1128/AAC.00051-09. Epub 2009 Jul 20.

12.

Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity.

Miro JM, Cervera C, Garcia-de-la-Maria C, Del Rio A, Armero Y, Mestres CA, Grau JM, Marco F, Moreno A.

Scand J Infect Dis. 2008;40(11-12):968-72. doi: 10.1080/00365540802398945.

PMID:
18767002
13.

Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Marco F, de la Mària CG, Armero Y, Amat E, Soy D, Moreno A, del Río A, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2008 Jul;52(7):2538-43. doi: 10.1128/AAC.00510-07. Epub 2008 Apr 21.

14.

Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Miró JM, García-de-la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de-Anta MT, Marco F; Hospital Clínic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2007 Jul;51(7):2373-7. Epub 2007 May 7.

Supplemental Content

Loading ...
Support Center